148 related articles for article (PubMed ID: 38069391)
21. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients.
Yu J; Ren X; Chen Y; Liu P; Wei X; Li H; Ying G; Chen K; Winkler H; Hao X
PLoS One; 2013; 8(2):e56069. PubMed ID: 23418512
[TBL] [Abstract][Full Text] [Related]
22. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.
Liu T; Li ZZ; Sun L; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Cancer; 2023 Oct; 23(1):1007. PubMed ID: 37858061
[TBL] [Abstract][Full Text] [Related]
23. PHF21A expression as a biomarker of hepatocellular carcinoma progression and prognosis.
Huang JQ; Ji LC; Jing QA; He YC; Ma YY; Tong XM
Neoplasma; 2022 Dec; 69(6):1349-1358. PubMed ID: 36305691
[TBL] [Abstract][Full Text] [Related]
24. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
25. Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma.
Yan J; Gao YM; Deng XL; Wang HS; Shi GT
BMC Cancer; 2023 Nov; 23(1):1161. PubMed ID: 38017425
[TBL] [Abstract][Full Text] [Related]
26. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma.
Shang BB; Chen J; Wang ZG; Liu H
PeerJ; 2021; 9():e12315. PubMed ID: 34754620
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining.
Le Y; Kong H; Gao X; Zhu J
Comput Math Methods Med; 2022; 2022():8371885. PubMed ID: 36017155
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatics analysis of LINC01554 and its co‑expressed genes in hepatocellular carcinoma.
Li L; Huang K; Lu Z; Zhao H; Li H; Ye Q; Peng G
Oncol Rep; 2020 Nov; 44(5):2185-2197. PubMed ID: 33000250
[TBL] [Abstract][Full Text] [Related]
29. [Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein].
Wang XJ; Shen RF; Wang X; Wang YR; Xiao T
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):396-402. PubMed ID: 32482029
[No Abstract] [Full Text] [Related]
30. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
32.
Liu S; Zhao W; Li X; Zhang L; Gao Y; Peng Q; Du C; Jiang N
Front Oncol; 2021; 11():713017. PubMed ID: 34595113
[TBL] [Abstract][Full Text] [Related]
33. Six2 is negatively correlated with prognosis and facilitates epithelial-mesenchymal transition via TGF-β/Smad signal pathway in hepatocellular carcinoma.
Wan ZH; Ma YH; Jiang TY; Lin YK; Shi YY; Tan YX; Dong LW; Wang HY
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):525-531. PubMed ID: 31564506
[TBL] [Abstract][Full Text] [Related]
34. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
35. Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Deng X; Zhao XF; Liang XQ; Chen R; Pan YF; Liang J
Biomed Pharmacother; 2017 Jun; 90():100-108. PubMed ID: 28343069
[TBL] [Abstract][Full Text] [Related]
36. ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis.
Wang X; Peng H; Zhang G; Li Z; Du Z; Peng B; Cao P
BMC Med Genomics; 2023 Jul; 16(1):178. PubMed ID: 37525242
[TBL] [Abstract][Full Text] [Related]
37. COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma.
Liu J; Han D; Xuan J; Xie J; Wang W; Zhou Q; Chen K
Aging (Albany NY); 2024 Mar; 16(6):5264-5287. PubMed ID: 38466642
[TBL] [Abstract][Full Text] [Related]
38. FOXP3 and SQSTM1/P62 correlate with prognosis and immune infiltration in hepatocellular carcinoma.
Liu S; Zhang H; Yan J; Zhu J; Bai Z; Li X
Pathol Res Pract; 2023 Feb; 242():154292. PubMed ID: 36630868
[TBL] [Abstract][Full Text] [Related]
39. HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway.
Yang G; Zhang M; Zhao Y; Pan Y; Kan M; Li J; He K; Zhang X
PLoS One; 2020; 15(3):e0230450. PubMed ID: 32210451
[TBL] [Abstract][Full Text] [Related]
40. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.
Zhao N; Chen C; Guo Y; Liu T; Che N; Zhang D; Liang X; Zhang Y; Zhao X
Dig Liver Dis; 2023 May; 55(5):661-672. PubMed ID: 36192339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
